The Depo-Provera debate. Commentary on the article "Depo-Provera, a critical analysis".
A widely publicized article has in recent months caused a great deal of concern among individuals interested in responsible promotion of family planning. The article contains a long series of factual errors, distortions and biased quotations. This commentary presents evidence, based on current knowledge, that Depo-Provera is a satisfactory contraceptive with several advantages and some disadvantages, and poses no more unresolved problems than oral contraceptives. There is no evidence that, at contraceptive doses, it increases the risk of cancer, impairs bone mineralization, "shocks" the hypothalamus, damages the liver or the immune system, or causes premature aging. Studies to date have not shown damaging effects on infants exposed to the drug in utero or via breast milk. To most women, disruption of the menstrual cycle, the major side effect, is not a health hazard. Finally, women in various parts of the world have shown to be quite capable of choosing for themselves whether or not the advantages of the drug can overcome the disadvantage of almost certain menstrual disturbance.
D000818:Animals; D001942:Breast Feeding; D050260:Carbohydrate Metabolism; D002273:Carcinogens; D003692:Delayed-Action Preparations; D004285:Dogs; D004717:Endometrium / Q000187:drug effects; D005193:Family Planning Services; D005260:Female; D000882:Haplorhini; D006801:Humans; D007165:Immunosuppression Therapy; D007231:Infant, Newborn; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000633:toxicity; D017258:Medroxyprogesterone Acetate; D008895:Milk, Human; D009369:Neoplasms / Q000139:chemically induced; D011247:Pregnancy; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
D002273:Carcinogens; D003692:Delayed-Action Preparations; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone